Physician profile
Joel Silver
NPI 1013976299
$57,259.92
in general payments reported to CMS, 2019-2025
41 companies · $43.04 in 2025
The $43.04 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,731 · 2020: $17K · 2021: $8,872 · 2022: $95.00 · 2023: $24K · 2024: $1,154 · 2025: $43.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $24K · Consulting Fee: $1,110 · Education: $44.00 · Food and Beverage: $43.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $24,200.00 |
| Consulting Fee | $1,110.00 |
| Education | $44.00 |
| Food and Beverage | $43.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $33,925.74 | 2019-2023 | |
| Daiichi Sankyo INC. | $14,154.01 | 2019-2021 | |
| Astellas Pharma US INC | $4,058.58 | 2019-2021 | |
| Seagen INC. | $1,416.61 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,274.50 | 2019-2025 | Tagrisso |
| Sanofi-Aventis U.S. LLC | $328.39 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $204.22 | 2019-2021 | |
| Janssen Biotech, INC. | $197.63 | 2019 | |
| Genentech USA, INC. | $171.27 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $145.37 | 2019-2020 | |
| Pfizer INC. | $125.11 | 2019-2020 | |
| Epizyme, INC. | $99.99 | 2021 | |
| Celgene Corporation | $84.81 | 2019 | |
| Genzyme Corporation | $81.67 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $73.34 | 2019-2024 | Rybrevant |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.